SCHEMBL29693297

SCHEMBL29693297

COC(=O)Nc1ccc(C(=O)NO)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.60
HDAC6 Q9UBN7 9/20 0.59
HDAC8 Q9BY41 7/20 0.59
HDAC3 O15379 5/20 0.59
HDAC11 Q96DB2 4/20 0.59
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
HDAC2 Q92769 3/20 0.56
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
TP53 P04637 1/20 0.55
ALOX15 P16050 1/20 0.55
HDAC1 Q13547 5/20 0.53
HPGD P15428 2/20 0.51
MAPT P10636 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9609808 0.83 SMN1; SMN2 (0.82) SMN1; SMN2NPC1RAB9AHPGDMAPT
SCHEMBL11658715 0.82 SMN1; SMN2 (0.67) SMN1; SMN2NPC1RAB9ATP53ALOX15
SCHEMBL12369268 0.81 MITF (0.64) SMN1; SMN2NPC1RAB9ATP53ALOX15
SCHEMBL22335189 0.80 KMT2A (0.56) SMN1; SMN2NPC1RAB9ATP53ALOX15
SCHEMBL674669 0.80 NPC1 (0.86) SMN1; SMN2HDAC6HDAC8HDAC3HDAC11
SCHEMBL2094519 0.80 SMN1; SMN2 (0.70) SMN1; SMN2CA1CA2NPC1RAB9A
SCHEMBL3001175 0.80 SMN1; SMN2 (0.64) SMN1; SMN2CA1CA2NPC1RAB9A
SCHEMBL8886838 0.80 MEN1 (0.69) SMN1; SMN2CA1CA2NPC1RAB9A
SCHEMBL14880210 0.80 CACNA1B (0.67) SMN1; SMN2HDAC6HDAC8HDAC3HDAC11
SCHEMBL15480476 0.80 SMN1; SMN2 (0.70) SMN1; SMN2HDAC6HDAC8HDAC3HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177421-A1 Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity ITALFARMACO SPA (IT) 2022-06-09 US claimed
US-20220177421-A1 Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity ITALFARMACO SPA (IT) 2022-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177421-A1 Process for preparing {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate having high purity H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1, CYP8B1 SMN1; SMN2 967/4885HDAC6 3807/4885HDAC8 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.